Eric Peterson
Cardiovascular Disease · Dallas, TXNPI 1720162613
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,367 of the $187,395 with a category attached, or 78.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 17.8%. Reporting peaked in 2019 at $80,605 and has fallen 99.7% since, to $253 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1601.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$33K
- Amgen$31K
- Sanofi-aventis U.S. LLC$20K
- Janssen Scientific Affairs, LLC$19K
- Novartis$15K
- Pfizer$12K
- plus $57K from 9 others
Across 25 payments — averaging $50,706 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.1M
- Esperion Therapeutics, Inc.$121K
- Janssen Scientific Affairs, LLC$15K
- Novo Nordisk$11K
- Novo Nordisk AS$5K
- Sanofi-aventis U.S. LLC$1K
- plus $490 from 1 others
What the payments were for
- Consulting fees$146,36778%
- Speaking & faculty fees$16,9809%
- Travel & lodging$21,05411%
- Food & beverage$2,9942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 28 | $33,426 |
| Amgen | 12 | $30,728 |
| Sanofi-aventis U.S. LLC | 6 | $19,921 |
| Janssen Scientific Affairs, LLC | 12 | $19,445 |
| Novartis | 6 | $14,869 |
| Pfizer | 7 | $12,420 |
| Amarin Pharma, Inc. | 20 | $12,369 |
| E.r. Squibb & Sons, L.L.C. | 4 | $11,538 |
| Abiomed | 5 | $7,526 |
| Idorsia Pharmaceuticals US Inc | 1 | $7,080 |
| AstraZeneca | 9 | $6,300 |
| Boehringer Ingelheim | 2 | $5,800 |
| Novo Nordisk | 2 | $5,663 |
| Astrazeneca UK Limited | 2 | $205 |
| Cleerly, Inc. | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$30,445
- Repatha$28,207
- PRALUENT$19,783
- XARELTO$19,138
- ELIQUIS$18,888
- Vascepa$11,933
- LEQVIO$10,950
- Impella$7,458
- Tryvio$7,080
- FARXIGA$6,163
- Non-Covered$2,480
- JARDIANCE$2,320
- RYBELSUS$1,163
- Cleerly Ischemia$105
- Cleerly Labs$105
How this compares
$187,395 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
- Subhash BanerjeeDallas$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.